Forecast Insight - Antidiabetics - Switching to new molecule antidiabetics drives market growth - www.companiesandmarkets.com adds new report.

2008-09-12 19:57:01 - Forecast Insight - Antidiabetics - Switching to new molecule antidiabetics drives market growth - a new market research report on www.companiesandmarkets.com

www.companiesandmarkets.com/Summary-Market-Report/Forecast-Insig ..

Introduction

Datamonitor expects the antidiabetics market to reach $29 billion, across the seven major markets, by 2017. The growth will be driven by the launch of new drug classes, notably the DPP-IV inhibitors and GLP-1 agonists, and large growth in patient numbers. However, patent expiries of the glitazone (TZDs) class will restrain market growth.

Scope

*Description of the competitive landscape in antidiabetics across seven major markets with market definition and overview.

*Event-driven updated sales forecasts for 2008-17 across the seven major markets: US, France, Germany, Italy, Spain, UK and Japan.

*Analysis of major events and brand dynamics affecting the diabetes market.

Highlights

The antidiabetics market in the seven major markets is expected to grow from $18 billion in 2007 to $29 billion in 2017 at a rate of 5% CAGR. Significant unmet needs remain in diabetes fueling a large pipeline. The epidemiological growth of the market, driven by the obesity epidemic and improved diagnosis rates, is further driving the market.

The glitazone class was the major non-insulin antidiabetic therapy in 2007 driven by the Actos and Avandia franchises. Both of these drugs will lose their marketing leading positions following patent expiry in 2011 and 2013. Safety concerns over Avandia remain unresolved and the drug will continue to continue to lose market share.

The incretin mimetics are likely to be the beneficiaries of Avandia´s problems and the DPP-IV inhibitors are expected to become the leading non-insulin antidiabetics. GLP-1 agonists are also expected to record significant sales. The two classes will provide over 75% of the sales from newly launched antidiabetics.

Reasons to Purchase

*Quantify the future size of the antidiabetics market and identify opportunities for new products.

*Learn how product expiries will shape the antidiabetics market.

*Understand the barriers to uptake for novel antidiabetic agents, and the implications of recent regulatory reviews.


www.companiesandmarkets.com/Summary-Market-Report/Forecast-Insig ..